Johnson & Johnson said on Thursday it had struck a deal with Emergent BioSolutions Inc to use its manufacturing facilities to help in an effort to make more than 1 billion doses of a vaccine it is testing to stop the novel coronavirus.
The U.S. healthcare conglomerate said the deal was the first in a series of prospective global partnerships to accelerate manufacturing of its experimental COVID-19 vaccine candidate, even before it has a signal that it works.